BUB1B and Miyoshi myopathy: Notably, the expression of BUB1B was evidently associated with inferior outcome in HOVON65 (p < 0.0001) (Fig. 1b) and TT2 (p < 0.0001) (Fig. 1c) patient cohorts, suggesting that BUB1B is a potential biomarker of MM poor prognosis.